

TRADEMARK ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Release Security Interest		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Parkedale Pharmaceuticals, Inc.		05/11/2010	CORPORATION: MICHIGAN
RECEIVING PARTY DATA			
Name:	Credit Suisse AG		
Street Address:	11 Madison Avenue		
Internal Address:	As Administrative Agent		
City:	New York		
State/Country:	NEW YORK		
Postal Code:	10010		
Entity Type:	Bank: SWITZERLAND		
PROPERTY NUMBERS Total: 7			
Property Type	Number	Word Mark	
Registration Number:	0883203	FLUOGEN	
Registration Number:	2577031	PARKEDALE PHARMACEUTICALS	
Registration Number:	2577032	PARKEDALE PHARMACEUTICALS	
Registration Number:	2628143	PARKEDALE PHARMACEUTICALS	
Registration Number:	2015950	PROCANBID	
Registration Number:	2065975	PROCANBID	
Registration Number:	2062311	PROCANBID	
CORRESPONDENCE DATA			
Fax Number:	(800)494-7512		
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>			
Phone:	(202) 370-4761		
Email:	ecallahan@nationalcorp.com		
Correspondent Name:	Elspeth Callahan		
Address Line 1:	1100 G St NW Suite 420		

OP \$190.00 0883203

900161921

TRADEMARK
REEL: 004203 FRAME: 0950

Address Line 2: National Corporate Research
Address Line 4: Washington, DISTRICT OF COLUMBIA 20005

ATTORNEY DOCKET NUMBER: F126672

NAME OF SUBMITTER: Mariee Pilkington

Signature: /Mariee Pilkington/

Date: 05/11/2010

Total Attachments: 3

source=T.Release - Parkedale Pharmaceuticals#page2.tif

source=T.Release - Parkedale Pharmaceuticals#page3.tif

source=T.Release - Parkedale Pharmaceuticals#page4.tif

Release of Security Interest in Trademarks

May 11, 2010

WHEREAS, King Pharmaceuticals, Inc., certain of its subsidiaries and Credit Suisse AG, Cayman Islands Branch (formerly Credit Suisse, Cayman Islands Branch) (“**Credit Suisse**”), in its capacity as Collateral Agent for the Secured Parties (as each term is defined in the GCA (as defined below)), entered into that certain Guarantee and Collateral Agreement (the “**GCA**”) dated December 29, 2008;

WHEREAS, pursuant to the GCA, Credit Suisse and Parkedale Pharmaceuticals, Inc. (the “**Assignee**”) entered into that certain Trademark Security Agreement dated December 29, 2008 and recorded with the United States Patent and Trademark Office on December 30, 2008 on Reel No. 3911, Frame 0744 (the “**Trademark Security Agreement**”);

WHEREAS, under the Trademark Security Agreement, the Assignee granted to Credit Suisse a security interest in certain Trademark Collateral (as defined in the Trademark Security Agreement), including those items set forth on Schedule 1 hereto (the “**Released Trademark Collateral**”); and

WHEREAS, Credit Suisse desires to release the security interest granted by the Assignee under the Trademark Security Agreement in the Released Trademark Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Credit Suisse, as Collateral Agent for the Secured Parties, does hereby unconditionally, irrevocably and absolutely terminate, release, extinguish and forever discharge the security interest granted under the Trademark Security Agreement in the Released Trademark Collateral, together with all of the goodwill of the business connected with the use of, or symbolized by, such Released Trademark Collateral, and hereby unconditionally, irrevocably and absolutely assigns, transfers and conveys to the Assignee all right, title and interest of Credit Suisse in, to and under such Released Trademark Collateral and such goodwill granted under the Trademark Security Agreement. This Release of Security Interest in Trademarks shall be binding upon Credit Suisse’s legal representatives, assigns and successors and upon the Secured Parties. Credit Suisse also hereby authorizes, and requests, the Director of the United States Patent and Trademark Office or his delegate to record this Release of Security Interest in Trademarks against the Released Trademark Collateral.

[signature page to follow]


IN WITNESS WHEREOF, Credit Suisse has caused this Release of Security Interest in Trademarks to be duly executed by its officer thereunto duly authorized as of the day and year first above written.

CREDIT SUISSE AG, CAYMAN
ISLANDS BRANCH

By: 

Name: DOREEN BARR

Title: DIRECTOR

By: 

Name: VIPUL DHADDA

Title: ASSOCIATE

[signature page – Parkedale trademark release]

Schedule 1

Parkedale Pharmaceuticals, Inc.

TRADEMARKS

Trademark	Registration #	Registration Date
FLUOGEN	883203	December 30, 1969
PARKEDALE PHARMACEUTICALS and Design	2577031	June 11, 2002
PARKEDALE PHARMACEUTICALS	2577032	June 11, 2002
PARKEDALE PHARMACEUTICALS	2628143	October 1, 2002
PROCANBID	2015950	November 12, 1996
PROCANBID and Design	2065975	May 27, 1997
PROCANBID and Design	2062311	May 13, 1997

TRADEMARK APPLICATIONS

None.

TRADEMARK LICENSES

None.